Expression of Survivin and KAI-1 in Gastric Adenocarcinomas.
10.5230/jkgca.2003.3.1.44
- Author:
Ju Han LEE
1
;
Byung Soo KIM
;
Jong Sang CHOI
Author Information
1. Department of Pathology, College of Medicine, Korea University, Seoul, Korea. jongchoi@kumc.or.kr
- Publication Type:Original Article
- Keywords:
Gastric adenocarcinoma;
Survivin;
KAI-1;
Immunohistochemistry;
Western blot
- MeSH:
Adenocarcinoma*;
Blotting, Western;
Classification;
Disease-Free Survival;
Humans;
Immunohistochemistry;
Prognosis;
Stomach Neoplasms;
Survival Rate
- From:Journal of the Korean Gastric Cancer Association
2003;3(1):44-49
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: The aim of this study was to investigate the impact of survivin expression and the decrease or loss of KAI-1 on the clinical stage and the survival rate in gastric adenocarcinomas. MATENRIALS AND METHODS: Expressions of survivin and KAI-1 were immunohistochemically determined in 40 cases of gastric adenocarcinomas. The survivin and KAI-1 expressions were also analyzed by using western blots in 14 cases among them. RESULTS: Resected gastric cancer specimens from 40 patients (intestinal type: 15 cases and diffuse type: 25 cases) were evaluated immunohistochemically. Survivin protein expressions were significantly higher in diffuse types (P=0.03) and in advanced clinical stages (UICC TNM II and III, P=0.02). In contrast, a decrease or loss of KAI-1 expression had no statistically significant correlation with the Lauren classification or the clinical stage. Survivin protein positivity was associated with an unfavorable prognosis. Decrease or loss of KAI-1 was associated with a shorter disease free survivial rate (P<0.01). The western blot data (n=14) indicated that neither survivin protein over-expression nor KAI-1 down-expression had an significant correlation with the Lauren classification or the clinical stage. CONCLUSION: In gastric carcinomas, survivin over-expression and decrease or loss of KAI-1 were associated with unfavorable prognosis, being independent prognostic factors along with the clinical stage and the disease free survival rate.
